Evidence map›Paper›PMID 39467118›Full record

ArticleProceedings of the National Academy of Sciences of the United States of America2024

Perturbation-specific transcriptional mapping for unbiased target elucidation of antibiotics.

Keith P Romano, Josephine Bagnall, Thulasi Warrier, Jaryd Sullivan, Kristina Ferrara, Marek Orzechowski, Phuong H Nguyen, Kyra Raines, Jonathan Livny, Noam Shoresh and 1 more

Abstract read
In one paragraph

Article in Proceedings of the National Academy of Sciences of the United States of America, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Distinctive Lacritin Cleavage-Potentiated Bactericidal Alteration of thebioRxiv : the preprint server for biology · 2026
    Article
  2. Article
  3. Article
  4. Article
  5. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

11 authors.

Keith P Romano *The Broad Institute of Massachusetts Institute of Technology and Harvard, Cambridge, MA 02142.ORCID 0000-0002-0623-8883
Josephine Bagnall *The Broad Institute of Massachusetts Institute of Technology and Harvard, Cambridge, MA 02142.ORCID 0000-0003-3415-3614
Thulasi Warrier *The Broad Institute of Massachusetts Institute of Technology and Harvard, Cambridge, MA 02142.
Jaryd Sullivan *The Broad Institute of Massachusetts Institute of Technology and Harvard, Cambridge, MA 02142.
Kristina FerraraThe Broad Institute of Massachusetts Institute of Technology and Harvard, Cambridge, MA 02142.
Marek OrzechowskiThe Broad Institute of Massachusetts Institute of Technology and Harvard, Cambridge, MA 02142.
Phuong H NguyenThe Broad Institute of Massachusetts Institute of Technology and Harvard, Cambridge, MA 02142.ORCID 0000-0001-6764-3957
Kyra RainesThe Broad Institute of Massachusetts Institute of Technology and Harvard, Cambridge, MA 02142.
Jonathan LivnyThe Broad Institute of Massachusetts Institute of Technology and Harvard, Cambridge, MA 02142.
Noam ShoreshThe Broad Institute of Massachusetts Institute of Technology and Harvard, Cambridge, MA 02142.
Deborah T HungThe Broad Institute of Massachusetts Institute of Technology and Harvard, Cambridge, MA 02142.

Funding

Innovative technologies to transform antibiotic discovery. Project 4 Infection site-specific amplification of antimicrobial conjugatesU19AI142780 · NIAID · BROAD INSTITUTE, INC. · PI HUNG, DEBORAH T · 2019 to 2023
$33.9M
Targeting lipopolysaccharide transport machinery in Pseudomonas aeruginosaK08AI148581 · NIAID · BRIGHAM AND WOMEN'S HOSPITAL · PI ROMANO, KEITH PATRICK · 2020 to 2024
$999k
HHS | NIH | National Institute of Allergy and Infectious Diseases (NIAID) NIH-1K08AI148581HHS | NIH | National Institute of Allergy and Infectious Diseases (NIAID) NIH-U19AI142780NIAID NIH HHS K08 AI148581NIAID NIH HHS U19 AI142780
6 · The paper itself

Abstract

The rising prevalence of antibiotic resistance threatens human health. While more sophisticated strategies for antibiotic discovery are being developed, target elucidation of new chemical entities remains challenging. In the postgenomic era, expression profiling can play an important role in mechanism-of-action (MOA) prediction by reporting on the cellular response to perturbation. However, the broad application of transcriptomics has yet to fulfill its promise of transforming target elucidation due to challenges in identifying the most relevant, direct responses to target inhibition. We developed an unbiased strategy for MOA prediction, called perturbation-specific transcriptional mapping (PerSpecTM), in which large-throughput expression profiling of wild-type or hypomorphic mutants, depleted for essential targets, enables a computational strategy to address this challenge. We applied PerSpecTM to perform reference-based MOA prediction based on the principle that similar perturbations, whether chemical or genetic, will elicit similar transcriptional responses. Using this approach, we elucidated the MOAs of three molecules with activity against

Indexed as

Anti-Bacterial AgentsPseudomonas aeruginosaDrug DiscoveryGene Expression ProfilingGene Expression Regulation, BacterialHumansMicrobial Sensitivity TestsTranscription, GeneticTranscriptomeAnti-Bacterial Agentsantibioticsgene expressionmechanism-of-actionRNAseqtranscriptomics

Identifiers

PMID39467118
PMCPMC11551328

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.